Rapamycin Augmentation of Chronic Ketamine as a Novel Treatment for Complex Regional Pain Syndrome
Authors:
Open Access
- 18 August 2023
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 15 (8) , e43715
Abstract
This case report describes the dramatic clinical response of refractory chronic complex regional pain syndrome to combined immunomodulatory treatment. Ketamine and rapamycin markedly minimized pain historically associated with suicidal behavior, increased baseline activity, and allowed for a reduction in palliative polypharmacy. The piecewise mechanism of action is unclear given multiple postulated targets, such as microglia, astroglia, T-regulatory cells, B-regulatory cells, or neurons. Relevant laboratory and genetic information may allow the application of this treatment to other affected individuals.Keywords
This publication has 42 references indexed in Scilit:
- Rapamycin Augments the NMDA-Mediated TNF Suppression of MRSA-Stimulated RAW264.7 Murine MacrophagesInternational Journal of Inflammation, 2012
- Constitutive reductions in mTOR alter cell size, immune cell development, and antibody productionBlood, 2011
- Inhibitory Effects of Ketamine on Lipopolysaccharide-Induced Microglial ActivationMediators of Inflammation, 2009
- Metabolic control of T cell activation and death in SLEAutoimmunity Reviews, 2008
- Low-dose ketamine affects immune responses in humans during the early postoperative periodBritish Journal of Anaesthesia, 2007
- Proposed New Diagnostic Criteria for Complex Regional Pain SyndromePain Medicine, 2007
- Risk Factors for Wound Healing Complications in Sirolimus-Treated Renal Transplant RecipientsTransplantation Proceedings, 2006
- Ketamine: a misunderstood analgesic?BMJ, 2006
- Glucose Metabolism in Renal Transplant RecipientsJournal of the American Society of Nephrology, 2005
- Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma*Pediatric Transplantation, 2004